Navigation Links
Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
Date:4/9/2008

SOUTH SAN FRANCISCO, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that data from a Phase 2 trial of picoplatin, the Company's lead product candidate, in patients with small cell lung cancer (SCLC) will be presented in a poster session at the 1st European Lung Cancer Conference in Geneva, Switzerland. The presentation is the first European presentation of data from the Phase 2 trial. The Conference is sponsored by the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO). Details are as follows:

-- Abstract #143

A Phase 2 study of picoplatin monotherapy in patients with platinum

refractory/resistant small cell lung cancer (SCLC)

Bentzion D, Lipatov O, Poliakov I, MacKintosh R, Breitz H. Eckardt J

Poster Session: SCLC: On display from 2:00 p.m. Wednesday, April 23,

through 12:30 p.m. Saturday, April 26

Geneva Palexpo Foyer Level 1

Presented by: John R. Eckardt, M.D., Center for Cancer Care Research,

Saint Louis, MO.

About Picoplatin

Picoplatin is a chemotherapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin has been evaluated in more than 750 patients and has anti-tumor activity in multiple indications with less severe kidney or nerve toxicity than is commonly observed with other platinum chemotherapy drugs.

Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
2. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
3. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
4. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
8. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
11. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Children aren,t the only segment of our ... disease. The Centers for Disease Control and Prevention ... many adults are not following this advice. ... and the American Lung Association in partnership with ... disease, to talk with their health care provider ...
(Date:8/20/2014)... Research and Markets has ... Wound Care and Closure Market (Types, Applications, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. The new ... market (types, applications, end user and geography) - ...
(Date:8/20/2014)... LYNDHURST, N.J. , Aug. 20, 2014  Amerigen ... Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA ... Mecobalamin 0.5 mg Tablets into the ... of a marketing and distribution agreement with Sinochem ... product at its US FDA approved and China ...
Breaking Medicine Technology:American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2
(Date:8/20/2014)... examined patient and tumor characteristics for melanomas with ... growth) in an effort to increase earlier detection ... , Author: Sarah Shen, M.B.B.S., B.Med.Sci., of ... Background: The tumor characteristic known as mitotic ... with prognosis and survival in melanoma patients. However, ...
(Date:8/20/2014)... 2014 Hundreds of Mirena IUD lawsuits ... who were allegedly injured due to spontaneous migration of ... Bergen County Superior Court, Bernstein Liebhard LLP reports. According ... 2014, the Court has established procedures regarding the production ... are part of the proceeding’s initial disposition pool. (In ...
(Date:8/20/2014)... Steven Reinberg HealthDay ... The speed at which cancer cells grow may help doctors ... Using this measure, investigators have found that the deadliest ... of older men with a long history of sun exposure. ... the researchers discovered. Rapid cell growth -- called ...
(Date:8/20/2014)... Aug. 20, 2014 A common approach to treating ... did not improve survival chances for people who suddenly ... at the University of Pittsburgh School of Medicine. , ... One , suggest acute hemodialysis, an aggressive method that ... may not provide a definitive benefit to the patient. ...
(Date:8/20/2014)... Research from Columbia University Medical Center shows that nerves ... and that blocking nerve signals using surgery or Botox ... The study was conducted by the laboratory of Timothy ... PhD, in Norway and is published in today,s issue ... long observed that human and mouse cancers contain a ...
Breaking Medicine News(10 mins):Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... MANHATTAN, Kan., Sept. 4 The path to poor hand sanitation ... and North Carolina State Universities. , , As ... fall, the researchers said students, actions will speak louder than words. ... their hands," said Douglas Powell, an associate professor of food safety ...
... , LOS ANGELES, Sept. 4 With an estimated ... is a TOP PRIORITY for the County,s working families and a key issue ... what is the eve of Congress, return to DC to debate healthcare reform, ... more about the importance of healthcare reform and to take action to be ...
... , , BATESVILLE, Ind., Sept. 4 ... fiscal 2009 fourth quarter dividend of $0.1025 per share. This dividend ... is payable on September 30, 2009 to shareholders of record as of ... HOLDINGS, INC. , Hill-Rom is a leading worldwide manufacturer and ...
... , MADISON, N.J., Sept. 4 Quest Diagnostics Incorporated ... information and services, today announced that it was again selected to be ... (DJSI World and DJSI North America). The company is in its sixth ... the North American Index (since 2005). , , According ...
... strategies , FRIDAY, Sept. 4 (HealthDay News) -- ... United Kingdom and Australia rethink their efforts to combat ... healthy diets and exercise -- aren,t working. , In ... , Australian researchers followed more than 250 overweight and ...
... WASHINGTON, Sept. 4 Nurses appear to be taking far better care ... survey released today by the Center for American Nurses and the Women,s ... Nurse Investor Education Survey reveals that nurses may be saving for retirement, ... most nurses say they do not know what those needs will be. ...
Cached Medicine News:Health News:Getting College Students To Wash Hands, Halt Disease, Requires Giving Them Proper Tools and Spreading The Word In Ways That Get Attention, Say K-State Expert and Colleague 2Health News:Labor Day Event to Offer Angelenos Unique Opportunity to Learn About Healthcare Reform and Send a Strong Message to Washington D.C.! 2Health News:Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index 2Health News:Nurses and Retirement Security: A Looming Crisis? 2Health News:Nurses and Retirement Security: A Looming Crisis? 3
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
Stryker Endoscopy has combined a standardized pressurizing system with an advanced hand piece design that is lightweight and compact in order to streamline laparoscopic procedures....
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... to disintegrate renal and ureteral ... technology in a compact design ... and affordable lithotripsy system. The ... of clinical results for both ...
Medicine Products: